BioCardia Regained Nasdaq Compliance After Price Drop

The company met minimum bid price requirements after shares struggled in recent trading sessions.

Updated on Sept. 22, 2026 in Public Companies

Bold flat-color editorial illustration of a sterile glass vial on a flat background, representing corporate regulatory compliance.
BioCardia has officially regained Nasdaq compliance after maintaining a share price above $1 for 10 consecutive business days. AI Illustration. Upload story photo >

Live Poll

Do you trust the long-term prospects of small biotech companies that struggle with stock listing requirements?

BioCardia has regained compliance with the Nasdaq minimum bid price requirement after maintaining a closing price of at least $1 for 10 consecutive business days. The announcement follows a period where the company previously fell out of compliance.

Why it matters

Maintaining Nasdaq compliance is essential for companies to avoid delisting, which can significantly impact liquidity and investor confidence. BioCardia remains cautious, noting no assurance that it will successfully maintain the $1 threshold in the future.

BioCardia shares closed at $1.08 in the regular session before falling 10.19 percent to $0.97 in after-hours trading. The company currently holds a market capitalization of approximately $16.35 million.

The players

BioCardia

This is a medical technology company that develops regenerative medicine and cardiovascular therapies.

Nasdaq

This is a global electronic marketplace for securities trading that enforces listing requirements for public companies.

The details

The firm faced regulatory scrutiny in August 2026 after trading below the $1 threshold for 30 consecutive business days. Despite regaining compliance, the stock has seen a 2.7 percent decline over the past 12 months, with 52-week extremes ranging from $0.75 to $1.80.

Timeline

  1. August 2026: BioCardia received the initial Nasdaq non-compliance notice.

  2. September 21, 2026: BioCardia shares traded in the regular session.

  3. September 21, 2026: Shares fell 10.19 percent during after-hours trading.

Market Landscape

This development reflects the ongoing pressure on small-cap firms to meet exchange listing standards to prevent potential delisting. Such compliance hurdles highlight the broader challenges companies with a market capitalization under $20 million face in maintaining investor interest.

Investors should note that while compliance is restored, the volatility of the stock price remains a factor for shareholder equity. The recent after-hours decline suggests continued market sensitivity regarding the company's valuation.

The takeaway

Maintaining listing requirements is a mandatory hurdle for small-cap stocks to avoid the liquidity risks associated with delisting. Investors should monitor future trading sessions closely to see if the company can sustain its current price level above the exchange-mandated minimum.

Further reading

For more information on market regulatory standards, visit the Public Companies section.

Live Poll

Do you trust the long-term prospects of small biotech companies that struggle with stock listing requirements?